Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Radiother Oncol. 2019 Apr;133:87-92. doi: 10.1016/j.radonc.2019.01.005. Epub 2019 Jan 21.
In locally advanced esophageal cancer, the optimal dose constraints for neoadjuvant chemoradiotherapy (NACRT) have yet to be established. This study is carried out to identify the most reliable dosimetric predictors for pulmonary complications following NACRT and surgery for esophageal cancer.
We retrospectively reviewed the medical records of 308 patients with esophageal cancer who received surgery following NACRT for locally advanced esophageal cancer from January 2005 to June 2017. Dose-volume histograms (DVH) of both lungs were computed for each patient along with total lung volume, mean lung dose (MLD), V, V, V, and V. The effect of each parameter on postoperative pulmonary complications was estimated in univariate and multivariate logistic regression analysis.
Postoperative pulmonary complications occurred in 22.1% of all patients. Univariate analysis for pulmonary complications showed that location of tumor (P = 0.017), pre-RT FEV1 (P = 0.003), MLD (P = 0.002), V (P < 0.001), V (P < 0.001), and V (P = 0.007) were all significant risk factors. Significant factors for postoperative pulmonary complications in multivariate analysis were MLD (odds ratio (OR) 1.118, 95% confidence interval (CI) 1.025-1.219, P = 0.012) and pre-RT FEV1 (OR 0.483, 95% CI 0.294-0.795, P = 0.004).
In patients who received NACRT and surgery for esophageal cancer, MLD was the parameter most related to postoperative pulmonary complications. Further studies are needed to establish the optimal DVH constraints for NACRT in order to minimize the risk of postoperative pulmonary complications in esophageal cancer patients.
在局部晚期食管癌中,新辅助放化疗(NACRT)的最佳剂量限制尚未确定。本研究旨在确定与接受 NACRT 联合手术治疗的局部晚期食管癌患者术后肺部并发症相关的最可靠剂量学预测因素。
回顾性分析 2005 年 1 月至 2017 年 6 月期间 308 例接受 NACRT 联合手术治疗的局部晚期食管癌患者的病历资料。计算每位患者的双肺剂量-体积直方图(DVH)以及全肺体积、平均肺剂量(MLD)、V、V、V 和 V。采用单因素和多因素逻辑回归分析评估各参数对术后肺部并发症的影响。
所有患者中术后肺部并发症的发生率为 22.1%。单因素分析显示,肿瘤位置(P=0.017)、放疗前 FEV1(P=0.003)、MLD(P=0.002)、V(P<0.001)、V(P<0.001)和 V(P=0.007)是术后肺部并发症的显著危险因素。多因素分析显示,MLD(比值比(OR)1.118,95%置信区间(CI)1.025-1.219,P=0.012)和放疗前 FEV1(OR 0.483,95%CI 0.294-0.795,P=0.004)是术后肺部并发症的显著因素。
在接受 NACRT 联合手术治疗的食管癌患者中,MLD 是与术后肺部并发症最相关的参数。为了降低食管癌患者术后肺部并发症的风险,需要进一步研究确定 NACRT 的最佳 DVH 限制。